BTIG says Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) “is surprising on the surface.” Investors did not expect Globus would ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...

Globus Medical Inc. (NYSE:GMED), a medical device company with a market capitalization of $12 billion and an "GREAT" financial health rating according to InvestingPro, reaffirmed its commitment to ...

The spinal surgical robots market is experiencing rapid growth as healthcare facilities worldwide adopt robotic-assisted technologies for spine surgeries. These robots enhance precision, reduce ...

Funding National Institute of Health Research, Guy's and St. Thomas’ Charity, Dystonia Society UK, Action Medical Research ... classical imaging findings of iron deposition in the globus pallidus and ...

Methods: Participants were scanned with both parallel imaging (PI)-QSM and DL-QSM methods ... Putamen, Pu; Caudate, Ca; external globus pallidus, GPe; internal globus pallidus, GPi; Red nucleus, RN; ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Globus Medical and Nevro Preliminary Full-Year 2024 Revenue Outlook: On January 8, 2025, Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year ...

Buying $100 In GMED: If an investor had bought $100 of GMED stock 10 years ago, it would be worth $356.36 today based on a price of $86.88 for GMED at the time of writing.

Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share.